Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2021
NICE recommends Inrebic for rare blood cancer
19 November 2021 - NICE have issued a final appraisal determination recommending the use of Inrebic (fedratinib) on the NHS for ...
Posted by Michael Wonder on 20 Nov 2021
NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement
19 November 2021 - Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit ...
Posted by Michael Wonder on 10 Nov 2021
NICE terminates appraisal of new, first in class radioenhancer hafnium oxide nanoparticle
10 November 2021 - NBTXR3 is used to treat patients with sarcoma. ...
Posted by Michael Wonder on 06 Nov 2021
NICE recommend dapagliflozin for people with chronic kidney disease
5 November 2021 - In draft guidance published today NICE has recommended dapagliflozin as an option for treating certain people ...
Posted by Michael Wonder on 04 Nov 2021
NICE recommends Namuscla for NHS to treat genetic disorder
4 November 2021 - NICE has published draft guidance which recommends a rebranded form of the drug mexiletine (Namuscla), for ...
Posted by Michael Wonder on 03 Nov 2021
NICE releases guidance on medicine for patients with thyroid cancer
3 November 2021 - Selpercatinib is used to treat patients with advanced RET fusion positive thyroid cancer. ...
Posted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...
Posted by Michael Wonder on 21 Oct 2021
NICE recommends gene silencing therapy for porphyria patients on NHS
21 October 2021 - NICE have recommended the use of givosiran, a gene silencing therapy, on the NHS in England, as ...
Posted by Michael Wonder on 18 Oct 2021
NICE approves Ofev for PF-ILD
18 October 2021 - NICE has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing ...
Posted by Michael Wonder on 18 Oct 2021
New asthma drug approved on NHS branded a ‘wonder drug’
18 October 2021 - NICE has issued a Final Appraisal Determination recommending dupilumab as an add-on maintenance treatment for severe ...
Posted by Michael Wonder on 15 Oct 2021
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
15 October 2021 - The UK NICE has recommended BMS' Opdivo (nivolumab) as a treatment option for certain resected oesophageal ...
Posted by Michael Wonder on 11 Oct 2021
Consternation as NICE rejects Janssen MS drug Ponvory
8 October 2021 - NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, ...
Posted by Michael Wonder on 06 Oct 2021
NICE terminates another appraisal for a Roche medicine
6 October 2021 - The sixth termination of the appraisal of a Roche medicine. ...
Posted by Michael Wonder on 05 Oct 2021
Venetoclax comes close to gaining support from NICE
4 October 2021 - A proposal from AbbVie for a Cancer Drugs Fund listing may get it over the line. ...
Posted by Michael Wonder on 05 Oct 2021
NICE recommends first treatment in two decades for sickle cell disease
5 October 2021 - Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance ...